SanBio Company Limited (4592.T)
JPY 2140.0
(7.0%)
JPY 2140.0
(7.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.53 Billion JPY | 42.54% |
| 2022 | -7.89 Billion JPY | -19.31% |
| 2021 | -6.62 Billion JPY | -14.12% |
| 2020 | -5.8 Billion JPY | -5.75% |
| 2019 | -5.48 Billion JPY | -46.93% |
| 2018 | -3.73 Billion JPY | 14.72% |
| 2017 | -4.37 Billion JPY | -126.6% |
| 2016 | -1.93 Billion JPY | -71.72% |
| 2015 | -1.12 Billion JPY | -150.04% |
| 2014 | 2.24 Billion JPY | 484.9% |
| 2013 | -584.24 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -905.34 Million JPY | -35.82% |
| 2024 Q1 | -666.58 Million JPY | 18.16% |
| 2023 Q4 | -814.45 Million JPY | -27.19% |
| 2023 Q3 | -640.32 Million JPY | 60.55% |
| 2023 Q1 | -1.46 Billion JPY | 2.23% |
| 2023 FY | -4.53 Billion JPY | 42.53% |
| 2023 Q2 | -1.62 Billion JPY | -11.04% |
| 2022 Q4 | -1.49 Billion JPY | 16.1% |
| 2022 Q2 | -2.77 Billion JPY | -50.59% |
| 2022 FY | -7.89 Billion JPY | -19.31% |
| 2022 Q1 | -1.84 Billion JPY | 1.95% |
| 2022 Q3 | -1.78 Billion JPY | 35.84% |
| 2021 Q4 | -1.88 Billion JPY | -11.5% |
| 2021 FY | -6.62 Billion JPY | -14.12% |
| 2021 Q1 | -1.54 Billion JPY | 4.53% |
| 2021 Q2 | -1.51 Billion JPY | 1.8% |
| 2021 Q3 | -1.68 Billion JPY | -11.53% |
| 2020 Q2 | -1.32 Billion JPY | -6.96% |
| 2020 Q4 | -1.61 Billion JPY | 0.25% |
| 2020 Q3 | -1.61 Billion JPY | -21.72% |
| 2020 FY | -5.8 Billion JPY | -5.75% |
| 2020 Q1 | -1.24 Billion JPY | 33.11% |
| 2019 FY | -5.48 Billion JPY | -46.93% |
| 2019 Q4 | -1.85 Billion JPY | -49.34% |
| 2019 Q3 | -1.24 Billion JPY | -9.44% |
| 2019 Q2 | -1.13 Billion JPY | 9.01% |
| 2019 Q1 | -1.24 Billion JPY | 0.46% |
| 2018 Q4 | -1.25 Billion JPY | -45.29% |
| 2018 Q3 | -863.5 Million JPY | -41.2% |
| 2018 Q2 | -611.53 Million JPY | 39.11% |
| 2018 Q1 | -1 Billion JPY | 16.93% |
| 2018 FY | -3.73 Billion JPY | 14.72% |
| 2017 Q3 | -1.02 Billion JPY | 9.5% |
| 2017 Q1 | -1.02 Billion JPY | -42.42% |
| 2017 FY | -4.37 Billion JPY | -126.6% |
| 2017 Q4 | -1.2 Billion JPY | -18.51% |
| 2017 Q2 | -1.12 Billion JPY | -10.33% |
| 2016 Q3 | -604.4 Million JPY | 12.1% |
| 2016 Q4 | -717.42 Million JPY | -18.7% |
| 2016 FY | -1.93 Billion JPY | -71.72% |
| 2016 Q2 | -687.62 Million JPY | -990.47% |
| 2016 Q1 | 77.22 Million JPY | 113.82% |
| 2015 Q3 | -10.68 Million JPY | 97.75% |
| 2015 FY | -1.12 Billion JPY | -150.04% |
| 2015 Q1 | -81.55 Million JPY | 50.04% |
| 2015 Q2 | -474.12 Million JPY | -481.39% |
| 2015 Q4 | -558.88 Million JPY | -5132.52% |
| 2014 FY | 2.24 Billion JPY | 484.9% |
| 2014 Q4 | -163.23 Million JPY | 0.0% |
| 2013 FY | -584.24 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 860.528% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | -813.522% |
| GNI Group Ltd. | 13.1 Billion JPY | 134.625% |
| Linical Co., Ltd. | 725.72 Million JPY | 725.444% |
| Trans Genic Inc. | 89.43 Million JPY | 5175.138% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | -218.314% |
| Soiken Holdings Inc. | -610 Million JPY | -644.09% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | -487.389% |
| AnGes, Inc. | -11.96 Billion JPY | 62.072% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | -304.979% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 52.351% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 4451.911% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | -425.095% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | -306.364% |
| CanBas Co., Ltd. | -1.26 Billion JPY | -259.667% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | -468.4% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -1245.427% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | -276.628% |
| Kidswell Bio Corporation | -1.33 Billion JPY | -239.848% |
| PeptiDream Inc. | 6.77 Billion JPY | 167.016% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | -135.183% |
| Ribomic Inc. | -1.11 Billion JPY | -306.65% |
| Healios K.K. | -3.37 Billion JPY | -34.33% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | -292.96% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | -225.724% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | -223.521% |
| StemRIM | -2.07 Billion JPY | -118.642% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 471.593% |
| FunPep Company Limited | -994 Million JPY | -356.64% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -410.71% |
| Stella Pharma Corporation | -760.3 Million JPY | -497.001% |
| TMS Co., Ltd. | -943.25 Million JPY | -381.207% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -485.382% |
| Cuorips Inc. | -588.48 Million JPY | -671.3% |
| K Pharma,Inc. | 366.05 Million JPY | 1339.971% |
| Takara Bio Inc. | 3 Billion JPY | 251.149% |
| ReproCELL Incorporated | -409.29 Million JPY | -1008.985% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 41128.654% |
| StemCell Institute Inc. | 413.75 Million JPY | 1197.015% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 3241.024% |
| CellSeed Inc. | -697.77 Million JPY | -550.495% |